DKK4 and neoplasm: Drug resistance and tumor recurrence are most of the concerns in clinical practices of GIST.42, 43 To deal with these, our study has revealed a novel tumor promoter, DKK4, which was upregulated by activated Wnt pathway in high‐risk GIST, promoting tumor progression via forming the immune suppressive microenvironment.